EGFR and lung adenocarcinoma: On the other hand, a prospective epidemiological study of EGFR mutations in patients from Asia with newly diagnosed stage IIIB/IV lung adenocarcinomas showed that the frequency of EGFR mutations was significantly higher among patients with stage IV compared with IIIB disease (53.5% vs. 43.2%; P = 0.009) [16].